NCT03150875View on ClinicalTrials.gov

A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC

PHASE3CompletedINTERVENTIONAL

Enrollment

290

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

February 22, 2023

Study Completion Date

February 22, 2023

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

IBI308

Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.

DRUG

Docetaxel

As 2nd line treatment to subjects with squamous NSCLC

Trial Locations (2)

Unknown

The First Affiliated Hospital Zhejiang University, Hangzhou

Jiangsu Cancer Hospital, Nanjing

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT03150875 - A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC | Biotech Hunter | Biotech Hunter